Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,342 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.5
Industry P/E
--
EV/EBITDA
-12.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.2
Face value
--
Shares outstanding
34,436,200
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Longboard Pharmaceuticals (LBPH)
| 894.7 | 0.4 | 80.3 | 1,173.5 | 115.9 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Longboard Pharmaceuticals (LBPH)
| 85.0 | -33.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Longboard Pharmaceuticals (LBPH)
|
60.0 | 2,342.0 | 0.0 | -76.3 | -1,093,125.0 | -25.9 | -- | 8.5 |
| 4.3 | 37.5 | 2.2 | -34.9 | -1,302.3 | -312.4 | -- | 7.6 | |
| 13.3 | 21.1 | 1.4 | -16.0 | -1,156.1 | -83.5 | -- | 1.1 | |
| 2.7 | 0.2 | 0.0 | -4.7 | -- | -134.8 | -- | 3.3 |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial... for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. As of December 2, 2024, Longboard Pharmaceuticals, Inc. operates as a subsidiary of Langkawi Corporation. Read more
President, CEO, Secretary & Director
Mr. Kevin R. Lind
President, CEO, Secretary & Director
Mr. Kevin R. Lind
Headquarters
La Jolla, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Longboard Pharmaceuticals Inc (LBPH) is $59.98 (NASDAQ) as of 13-Dec-2024 09:30 EDT. Longboard Pharmaceuticals Inc (LBPH) has given a return of 115.9% in the last 3 years.
Since, TTM earnings of Longboard Pharmaceuticals Inc (LBPH) is negative, P/E ratio is not available.
The P/B ratio of Longboard Pharmaceuticals Inc (LBPH) is 8.51 times as on 13-Dec-2024, a 116 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-2.65
|
3.53
|
|
2022
|
-1.30
|
0.91
|
|
2021
|
-3.00
|
0.80
|
|
2020
|
--
|
--
|
|
2023
|
-2.65
|
3.53
|
The 52-week high and low of Longboard Pharmaceuticals Inc (LBPH) are Rs -- and Rs -- as of 03-Apr-2026.
Longboard Pharmaceuticals Inc (LBPH) has a market capitalisation of $ 2,342 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Longboard Pharmaceuticals Inc (LBPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.